JP7707081B2 - 網膜細胞を標的とした最適化された遺伝子治療 - Google Patents
網膜細胞を標的とした最適化された遺伝子治療 Download PDFInfo
- Publication number
- JP7707081B2 JP7707081B2 JP2021568813A JP2021568813A JP7707081B2 JP 7707081 B2 JP7707081 B2 JP 7707081B2 JP 2021568813 A JP2021568813 A JP 2021568813A JP 2021568813 A JP2021568813 A JP 2021568813A JP 7707081 B2 JP7707081 B2 JP 7707081B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- leu
- gene therapy
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01129—Endo-alpha-sialidase (3.2.1.129)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849794P | 2019-05-17 | 2019-05-17 | |
| US62/849,794 | 2019-05-17 | ||
| PCT/US2020/028352 WO2020236352A1 (en) | 2019-05-17 | 2020-04-15 | Optimized gene therapy targeting retinal cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533983A JP2022533983A (ja) | 2022-07-27 |
| JP2022533983A5 JP2022533983A5 (cg-RX-API-DMAC7.html) | 2023-04-25 |
| JP7707081B2 true JP7707081B2 (ja) | 2025-07-14 |
Family
ID=70482910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568813A Active JP7707081B2 (ja) | 2019-05-17 | 2020-04-15 | 網膜細胞を標的とした最適化された遺伝子治療 |
| JP2021568543A Pending JP2022533645A (ja) | 2019-05-17 | 2020-04-15 | グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568543A Pending JP2022533645A (ja) | 2019-05-17 | 2020-04-15 | グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220226507A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3969059A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7707081B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220009427A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114126667A (cg-RX-API-DMAC7.html) |
| AR (1) | AR118696A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020278960A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3141020A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202110486A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020236351A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020154535A1 (en) | 2019-01-23 | 2020-07-30 | University Of Florida Research Foundation, Incorporated | Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design |
| US12019249B2 (en) * | 2019-12-25 | 2024-06-25 | Lumus Ltd. | Optical systems and methods for eye tracking based on redirecting light from eye using an optical arrangement associated with a light-guide optical element |
| CN114516901B (zh) * | 2022-03-11 | 2023-01-17 | 上海勉亦生物科技有限公司 | 一种神经系统高亲和性的aav载体及其应用 |
| CN115323001B (zh) * | 2022-07-28 | 2024-11-26 | 深圳先进技术研究院 | 一种靶向视网膜的基因递送系统及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015525783A (ja) | 2012-08-01 | 2015-09-07 | ネイションワイド チルドレンズ ホスピタル | 組換えアデノ随伴ウイルス9の髄腔内送達 |
| WO2017218450A1 (en) | 2016-06-13 | 2017-12-21 | The University Of North Carolina At Chapel Hill | Optimized cln1 genes and expression cassettes and their use |
| JP2018500311A (ja) | 2014-12-16 | 2018-01-11 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| JP2018521670A (ja) | 2015-07-30 | 2018-08-09 | マサチューセッツ アイ アンド イヤー インファーマリー | 祖先ウイルス配列およびその使用 |
| JP2018535955A (ja) | 2015-10-23 | 2018-12-06 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 認知保護を提供しつつ疾患の発症及び進行を遅らせるための遺伝子治療を用いた神経変性疾患の治療方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| DE69433922T2 (de) | 1993-11-09 | 2005-07-28 | Medical College Of Ohio, Toledo | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびaavの精製 |
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| EP1696036B1 (en) | 1996-09-06 | 2010-04-21 | The Trustees of The University of Pennsylvania | Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| CA2995542A1 (en) | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| WO2012109214A1 (en) * | 2011-02-07 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Targeted transduction of aav vectors |
| CN103502458B (zh) * | 2011-02-17 | 2016-11-16 | 宾夕法尼亚大学托管会 | 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法 |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| AU2014243925B2 (en) * | 2013-03-14 | 2018-12-06 | Wayne State University | Method of enhancing delivery of therapeutic compounds to the eye |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015126972A1 (en) * | 2014-02-21 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Methods and compositions for gene delivery to on bipolar cells |
| GB201403260D0 (en) * | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| LT3137497T (lt) * | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| JP6684343B2 (ja) * | 2015-05-21 | 2020-04-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子の相乗組み合わせ及びその使用 |
| EP3516046B1 (en) * | 2016-09-22 | 2022-07-13 | Sorbonne Université | Optogenetically transformed photoreceptor precursor cells for the use in the treatment of retinal degenerative diseases |
| MX2020003945A (es) * | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente . |
-
2020
- 2020-04-15 JP JP2021568813A patent/JP7707081B2/ja active Active
- 2020-04-15 WO PCT/US2020/028207 patent/WO2020236351A1/en not_active Ceased
- 2020-04-15 CN CN202080051735.0A patent/CN114126667A/zh active Pending
- 2020-04-15 AR ARP200101063A patent/AR118696A1/es unknown
- 2020-04-15 JP JP2021568543A patent/JP2022533645A/ja active Pending
- 2020-04-15 CA CA3141020A patent/CA3141020A1/en active Pending
- 2020-04-15 WO PCT/US2020/028352 patent/WO2020236352A1/en not_active Ceased
- 2020-04-15 US US17/611,982 patent/US20220226507A1/en active Pending
- 2020-04-15 EP EP20723738.9A patent/EP3969059A1/en active Pending
- 2020-04-15 AU AU2020278960A patent/AU2020278960A1/en active Pending
- 2020-04-15 US US17/611,972 patent/US20220233655A1/en not_active Abandoned
- 2020-04-15 KR KR1020217040926A patent/KR20220009427A/ko not_active Withdrawn
- 2020-04-15 AU AU2020278499A patent/AU2020278499A1/en active Pending
- 2020-04-15 TW TW109112715A patent/TW202110486A/zh unknown
- 2020-04-15 EP EP20727414.3A patent/EP3969060A1/en active Pending
- 2020-04-15 CA CA3141017A patent/CA3141017A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015525783A (ja) | 2012-08-01 | 2015-09-07 | ネイションワイド チルドレンズ ホスピタル | 組換えアデノ随伴ウイルス9の髄腔内送達 |
| JP2018500311A (ja) | 2014-12-16 | 2018-01-11 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| JP2018521670A (ja) | 2015-07-30 | 2018-08-09 | マサチューセッツ アイ アンド イヤー インファーマリー | 祖先ウイルス配列およびその使用 |
| JP2018535955A (ja) | 2015-10-23 | 2018-12-06 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 認知保護を提供しつつ疾患の発症及び進行を遅らせるための遺伝子治療を用いた神経変性疾患の治療方法 |
| WO2017218450A1 (en) | 2016-06-13 | 2017-12-21 | The University Of North Carolina At Chapel Hill | Optimized cln1 genes and expression cassettes and their use |
Non-Patent Citations (9)
| Title |
|---|
| Cell Reports,2015年,12,pp.1056-1068 |
| Experimental Eye Research,2011年,93,pp.491-502 |
| Molecular Therapy,2015年,23(2),pp.290-296,doi:10.1038/mt.2014.181 |
| Molecular Therapy,2017年,25(5), Suppl.1,p.106, Abstract Number: 223 |
| Molecular Therapy,2018年05月,26(5),pp.1343-1353 |
| NEUROLOGY,2019年03月,Vol.15,pp.161-178 |
| Neuroscience,2018年,381,pp.1-10 |
| Ophthamology,2003年,110(6),pp.1241-1244 |
| 臨床眼科,2014年,68(5),pp.661-664 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114126667A (zh) | 2022-03-01 |
| EP3969059A1 (en) | 2022-03-23 |
| AR118696A1 (es) | 2021-10-27 |
| AU2020278499A1 (en) | 2022-01-06 |
| CA3141017A1 (en) | 2020-11-26 |
| US20220226507A1 (en) | 2022-07-21 |
| WO2020236352A1 (en) | 2020-11-26 |
| JP2022533983A (ja) | 2022-07-27 |
| AU2020278960A1 (en) | 2021-12-23 |
| WO2020236351A1 (en) | 2020-11-26 |
| TW202110486A (zh) | 2021-03-16 |
| JP2022533645A (ja) | 2022-07-25 |
| KR20220009427A (ko) | 2022-01-24 |
| US20220233655A1 (en) | 2022-07-28 |
| EP3969060A1 (en) | 2022-03-23 |
| CA3141020A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11236402B2 (en) | Adeno-associated virus virions with variant capsid | |
| US11072803B2 (en) | Hybrid dual recombinant AAV vector systems for gene therapy | |
| US20210177990A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| US20220226507A1 (en) | Optimized gene therapy targeting retinal cells | |
| US12097267B2 (en) | Methods and compositions for treatment of ocular disorders and blinding diseases | |
| JP2025093922A (ja) | Cln6ポリヌクレオチドのアデノ随伴ウイルス送達 | |
| JP2025138648A (ja) | Cln3ポリヌクレオチドのアデノ随伴ウイルス送達 | |
| US20230338582A1 (en) | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | |
| JP7781057B2 (ja) | Irf2bpl遺伝子の変異に関連する障害の治療のための材料および方法 | |
| WO2023111106A1 (en) | Fukutin related protein gene transfer increase using modified itr sequences | |
| CA3131923A1 (en) | Neuroprotective gene therapy targeting the akt pathway | |
| JP2026503144A (ja) | 発現を調節するための物質及び方法 | |
| EP4198046A1 (en) | Alpha-sarcoglycan gene transfer increase using modified itr sequences | |
| JP2025524569A (ja) | Cln1ポリヌクレオチドのアデノ随伴ウイルス送達 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230417 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230417 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240321 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240321 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240620 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250313 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250627 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250702 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7707081 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |